Dong-A ST

Products the company presents as its flagship domestically developed new drugs; Stillen is a gastritis treatment.

Oxyntomodulin-analog obesity candidate acting on both GLP-1 and glucagon receptors, developed with affiliate MetaVia; the 48 mg high-dose cohort of the global phase 1 showed an average 9.1% weight reduction at day 54.

Candidate for metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes that has completed a global phase 2a trial.

The Cheonan campus makes tablets, capsules and general and oncology injectables; the Daegu campus makes Growtropin pens and vials and prefilled syringes; the Songdo campus, completed in 2022, is preparing for tablet production.

Signed an exclusive Korean distribution agreement with Salted for NeuroGait, a smart-insole AI gait analysis solution; Dong-A ST handles distribution, sales and marketing, and Salted handles product supply and technical support.

The Dong-A Socio Group built the AI drug discovery platform AIDDP and began applying AI across its R&D work.

Reported record quarterly revenue of 207.8 billion won for the second quarter of 2026, with growth across all business divisions.

With MetaVia, presented high-dose phase 1 results for DA-1726 at the American Diabetes Association (ADA); no serious treatment-related adverse events or discontinuations were reported.